1. A Novel NF‐κB Inhibitor, Edasalonexent (CAT‐1004), in Development as a Disease‐Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects. (11th January 2017) Authors: Donovan, Joanne M.; Zimmer, Michael; Offman, Elliot; Grant, Toni; Jirousek, Michael Journal: Journal of clinical pharmacology Issue: Volume 57:Number 5(2017) Page Start: 627 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗